People | July 16, 2022
Enveda appoints Vanitha Sekar as Chief Business Officer
She joins Enveda from Gilead Sciences
She joins Enveda from Gilead Sciences
First and only PARP inhibitor to improve invasive disease-free survival in patients
V116 designed to target serotypes that account for 85% of all invasive pneumococcal disease in individuals aged 65 and over in the United States as of 2019
LYNPARZA is approved in the U.S. for patients with HRR gene-mutated mCRPC (BRCA-mutated and other HRR gene mutations)
Acceptance based on results from the phase 3 KEYNOTE-091 trial
Based on a post hoc analysis, fewer required respiratory interventions
Immune-mediated events and infusion reactions were higher with KEYTRUDA (38% vs 9%, respectively).
Among patients with infectious virus at baseline, no patients who received Lagevrio had infectious virus at days 3, 5 or 10
No new studies have been requested
The approval is based on new data from cohorts D and K of the KEYNOTE-158 trial
Subscribe To Our Newsletter & Stay Updated
